These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36096757)

  • 21. Polygenic analysis suggests the involvement of calcium signaling in executive function in schizophrenia patients.
    Kirchner SK; Ozkan S; Musil R; Spellmann I; Kannayian N; Falkai P; Rossner M; Papiol S
    Eur Arch Psychiatry Clin Neurosci; 2020 Jun; 270(4):425-431. PubMed ID: 30523404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Pattern of Cognitive Deficits Stratified for Genetic and Environmental Risk Reliably Classifies Patients With Schizophrenia From Healthy Control Subjects.
    Antonucci LA; Pergola G; Pigoni A; Dwyer D; Kambeitz-Ilankovic L; Penzel N; Romano R; Gelao B; Torretta S; Rampino A; Trojano M; Caforio G; Falkai P; Blasi G; Koutsouleris N; Bertolino A
    Biol Psychiatry; 2020 Apr; 87(8):697-707. PubMed ID: 31948640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in olfactory dysfunction and its relationship with cognitive function in schizophrenia patients with and without auditory verbal hallucinations.
    Wang Q; Ren H; Li Z; Li J; Dai L; Dong M; Zhou J; He J; Chen X; Gu L; He Y; Tang J
    Eur Arch Psychiatry Clin Neurosci; 2023 Dec; 273(8):1813-1824. PubMed ID: 36949249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-response effect of acute phencyclidine on functional connectivity and dopamine levels, and their association with schizophrenia-like symptom classes in rat.
    Paasonen J; Salo RA; Ihalainen J; Leikas JV; Savolainen K; Lehtonen M; Forsberg MM; Gröhn O
    Neuropharmacology; 2017 Jun; 119():15-25. PubMed ID: 28342897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pragmatic deficits in patients with schizophrenia and right hemisphere damage: A pilot study.
    Chakrabarty M; Bhattacharya K; Chatterjee G; Biswas A; Ghosal M
    Int J Lang Commun Disord; 2023 Jan; 58(1):169-188. PubMed ID: 36073996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Impact of Negative Symptoms and Neurocognition on Functioning in MDD and Schizophrenia.
    Quek YF; Yang Z; Dauwels J; Lee J
    Front Psychiatry; 2021; 12():648108. PubMed ID: 34381384
    [No Abstract]   [Full Text] [Related]  

  • 27. Color discrimination in schizophrenia.
    Shuwairi SM; Cronin-Golomb A; McCarley RW; O'Donnell BF
    Schizophr Res; 2002 May; 55(1-2):197-204. PubMed ID: 11955979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polygenic Risk of Schizophrenia and Cognition in a Population-Based Survey of Older Adults.
    Liebers DT; Pirooznia M; Seiffudin F; Musliner KL; Zandi PP; Goes FS
    Schizophr Bull; 2016 Jul; 42(4):984-91. PubMed ID: 26873889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Self-Evaluation of Negative Symptoms in Differentiating Deficit Schizophrenia: The Comparison of Sensitivity and Specificity with Other Tools.
    Samochowiec J; Jabłoński M; Plichta P; Piotrowski P; Stańczykiewicz B; Bielawski T; Misiak B
    Psychopathology; 2023; 56(6):453-461. PubMed ID: 36878191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of implementation intentions on prospective memory performance in patients with schizophrenia: A multinomial modeling approach.
    Liu LL; Wang Y; Cui JF; Li Y; Yang TX; Chen T; Neumann DL; Shum DH; Chan RC
    Schizophr Res; 2020 Jan; 215():120-125. PubMed ID: 31784339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive Function in Individuals With Psychosis: Moderation by Adolescent Cannabis Use.
    Hanna RC; Shalvoy A; Cullum CM; Ivleva EI; Keshavan M; Pearlson G; Hill SK; Sweeney JA; Tamminga CA; Ghose S
    Schizophr Bull; 2016 Nov; 42(6):1496-1503. PubMed ID: 27033329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A narrative review of treatment interventions to improve cognitive performance in schizophrenia, with an emphasis on at-risk and early course stages.
    Mayeli A; Clancy KJ; Sonnenschein S; Sarpal DK; Ferrarelli F
    Psychiatry Res; 2022 Nov; 317():114926. PubMed ID: 36932470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlations between age, biomedical variables, and cognition in patients with schizophrenia.
    Tang W; Fan KL; Zhao SZ; Zhang YY; Li Y; Shao SM; Wang Z; Ke JQ
    Schizophr Res Cogn; 2020 Dec; 22():100182. PubMed ID: 32577406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hippocampal Subfield Volumes and Cognitive Function in Schizophrenia and Mood Disorders.
    Yasuda K; Yamada S; Uenishi S; Ikeda N; Tamaki A; Ohoshi Y; Tsuji T; Takahashi S
    Neuropsychobiology; 2022; 81(3):204-214. PubMed ID: 35034014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polygenic Risk Scores Differentiating Schizophrenia From Bipolar Disorder Are Associated With Premorbid Intelligence in Schizophrenia Patients and Healthy Subjects.
    Ohi K; Nishizawa D; Sugiyama S; Takai K; Kuramitsu A; Hasegawa J; Soda M; Kitaichi K; Hashimoto R; Ikeda K; Shioiri T
    Int J Neuropsychopharmacol; 2021 Jul; 24(7):562-569. PubMed ID: 33738471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cognition, schizophrenia and the effect of antipsychotics].
    Stip E
    Encephale; 2006; 32(3 Pt 1):341-50. PubMed ID: 16840928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do sleep disturbances contribute to cognitive impairments in schizophrenia spectrum and bipolar disorders?
    Laskemoen JF; Büchmann C; Barrett EA; Collier-Høegh M; Haatveit B; Vedal TJ; Ueland T; Melle I; Aas M; Simonsen C
    Eur Arch Psychiatry Clin Neurosci; 2020 Sep; 270(6):749-759. PubMed ID: 31587109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Theory of mind impairment and its clinical correlates in patients with schizophrenia, major depressive disorder and bipolar disorder.
    Wang YY; Wang Y; Zou YM; Ni K; Tian X; Sun HW; Lui SSY; Cheung EFC; Suckling J; Chan RCK
    Schizophr Res; 2018 Jul; 197():349-356. PubMed ID: 29122405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study.
    Fusar-Poli L; Prachason T; Erzin G; Pries LK; Brondino N; Politi P; Delespaul P; Kenis G; Luykx JJ; Lin BD; Richards AL; Akdede B; Binbay T; Altınyazar V; Yalınçetin B; Gümüş-Akay G; Cihan B; Soygür H; Ulaş H; Cankurtaran EŞ; Kaymak SU; Mihaljevic MM; Andric-Petrovic S; Mirjanic T; Bernardo M; Mezquida G; Amoretti S; Bobes J; Saiz PA; García-Portilla MP; Sanjuan J; Escarti MJ; Santos JL; Jiménez-López E; Arrojo M; Carracedo A; López G; González-Peñas J; Parellada M; Maric NP; Atbaşoğlu C; Üçok A; Alptekin K; Saka MC; Arango C; O'Donovan M; van Os J; Rutten BP; Guloksuz S;
    Psychiatry Res; 2023 May; 323():115184. PubMed ID: 37015164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia.
    Girgis RR; Van Snellenberg JX; Glass A; Kegeles LS; Thompson JL; Wall M; Cho RY; Carter CS; Slifstein M; Abi-Dargham A; Lieberman JA
    J Psychopharmacol; 2016 May; 30(5):428-35. PubMed ID: 26966119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.